| abstract |
The compounds, their pharmaceutically acceptable salts, in the form of individual enantiomers, racemates or other mixtures of enantiomers, are used to treat disorders of the central nervous system, such as depression, fear, psychosis (eg schizophrenia), delayed dyskinesia, Parkinson's disease, obesity , high blood pressure, Touret syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive impairment, Alzheimer's disease, senile dementia, manic-obsessive behavior, seizures, and panic, eating disorders and anorexia, cardiovascular and cerebrovascular diseases, insulin-dependent diabetes mellitus, hyperglycemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy and cerebral paralysis. They exhibit both affinity for 5-HT1A and D2 receptors. The compounds have the formula @@ wherein A is -O-; B is -O-; g is 0 or 1; U is methylene; Q is a group of formula IIa or IIc as described in the description. |